The following is a summary of the Terumo Corporation (TRUMY) Q4 2024 Earnings Call Transcript:

Financial Performance:

• Terumo Corporation saw record highs in sales revenue, operating income, and net income for the fiscal year ending March 31, 2024. Revenue, driven primarily by the US and European markets, grew by 7%.

• Net income surpassed JPY 100 billion to reach JPY 106.4 billion, with revenue for the full year exceeding JPY 920 billion.

• The company projects a 7% revenue growth and 16% increase in operating income for FY '24, excluding the effects of exchange rates.

• The dividend for FY '23 was set at JPY 22 per share with a payout ratio of 30.8%, and the forecasted dividend for FY '24 is JPY 26 per share, expected to raise the payout ratio to 31.6%.

Business Progress:

• Terumo Corporation expects continuous global growth and plans to expand its highly profitable businesses in FY '24.

• The company aims to bolster its profitability through company-wide measures while also propelling growth drivers in the next fiscal year.

• As part of its GS26 strategy, the company is open to further mergers and acquisitions, leveraging its strong financial position to optimize its portfolio.

• Terumo is dedicated to long-term strategies aiming at improving patient quality of life, expanding its reach beyond traditional medical device manufacturing, and resolving complex medical issues via innovation and partnerships.

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.